Abstract
During an average follow-up of 4.1 years, treatment with oral conjugated equine estrogen plus medroxyprogesterone acetate did not reduce the overall rate of CHD events in postmenopausal women with established coronary disease. The treatment did increase the rate of thromboembolic events and gallbladder disease. Based on the finding of no overall cardiovascular benefit and a pattern of early increase in risk of CHD events, we do not recommend starting this treatment for the purpose of secondary prevention of CHD. However, given the favorable pattern of CHD events after several years of therapy, it could be appropriate for women already receiving this treatment to continue.
Keywords
MedicineMedroxyprogesterone acetateMyocardial infarctionHazard ratioInternal medicineUnstable anginaPlaceboRandomized controlled trialCardiologyCoronary artery diseaseAnginaStroke (engine)Hormone therapyHeart failureRelative riskEstrogenConfidence intervalBreast cancerCancer
Affiliated Institutions
Related Publications
HORMONE REPLACEMENT THERAPY, HEART DISEASE, AND OTHER CONSIDERATIONS
▪ Abstract Multiple observational studies suggest a marked reduction in risk of coronary heart disease (CHD) associated with postmenopausal estrogen use. A new meta-analysis pre...
Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled Trial
Overall health risks exceeded benefits from use of combined estrogen plus progestin for an average 5.2-year follow-up among healthy postmenopausal US women. All-cause mortality ...
Medroxyprogesterone Acetate Antagonizes Inhibitory Effects of Conjugated Equine Estrogens on Coronary Artery Atherosclerosis
Although estrogen replacement therapy is associated with reduced risk of coronary heart disease and reduced extent of coronary artery atherosclerosis, the effects of combined (e...
Renal Insufficiency and the Risk of Lower Extremity Peripheral Arterial Disease
Renal insufficiency is a risk factor for coronary heart disease and stroke, but whether it predicts lower extremity peripheral arterial disease (PAD) is unknown. The authors eva...
Hormone Therapy To Prevent Disease and Prolong Life in Postmenopausal Women
Hormone therapy should probably be recommended for women who have had a hysterectomy and for those with coronary heart disease or at high risk for coronary heart disease. For ot...
Publication Info
- Year
- 1998
- Type
- article
- Volume
- 280
- Issue
- 7
- Pages
- 605-605
- Citations
- 6215
- Access
- Closed
External Links
Social Impact
Altmetric
PlumX Metrics
Social media, news, blog, policy document mentions
Citation Metrics
6215
OpenAlex
Cite This
Stephen B. Hulley
(1998).
Randomized Trial of Estrogen Plus Progestin for Secondary Prevention of Coronary Heart Disease in Postmenopausal Women.
JAMA
, 280
(7)
, 605-605.
https://doi.org/10.1001/jama.280.7.605
Identifiers
- DOI
- 10.1001/jama.280.7.605